Korea Exchange · Healthcare
Jeil Pharmaceutical stock from India: price, numbers and tax
Jeil Pharmaceutical (271980) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Jeil Pharmaceutical at a glance
- Price
- ₩10,050.00-₩280.00 (2.71%)
- Market cap
- ₩147.78B
- Day range
- ₩9,980.00 – ₩10,330.00
- P/E
- 8.27
- Dividend yield
- None
- Volume
- 22.96K
- 1 month
- -2.80%
- 6 months
- -22.93%
- YTD
- -33.66%
- 1 year
- -33.66%
- 5 years
- -70.87%
Jeil Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩566.3B | ₩704.5B | ₩726.4B | ₩722.2B | ₩700.7B |
| Gross profit | ₩208.4B | ₩177.5B | ₩184.3B | ₩156.8B | ₩156.0B |
| Operating income | ₩20.3B | −₩18.9B | ₩8.7B | −₩13.5B | −₩10.4B |
| Net income | ₩23.4B | −₩30.0B | ₩5.0B | −₩13.1B | −₩12.5B |
| Earnings per share | ₩1,604.77 | −₩2,056.36 | ₩343.46 | −₩898.19 | −₩853.81 |
| EBITDA | ₩32.6B | −₩10.6B | ₩17.7B | −₩1.2B | −₩2.0B |
| Total assets | ₩510.6B | ₩525.7B | ₩487.3B | ₩456.9B | ₩426.5B |
| Total debt | ₩93.4B | ₩75.7B | ₩71.2B | ₩50.4B | ₩47.8B |
| Cash and short-term investments | ₩58.8B | ₩57.5B | ₩35.7B | ₩31.6B | ₩28.0B |
| Shareholders' equity | ₩211.1B | ₩188.1B | ₩158.6B | ₩157.9B | ₩168.2B |
| Operating cash flow | −₩5.7B | ₩3.2B | −₩5.0B | −₩15.1B | ₩19.1B |
| Free cash flow | −₩13.7B | −₩3.4B | −₩14.6B | −₩32.1B | ₩13.7B |
| Capital expenditure | −₩8.0B | −₩6.6B | −₩9.6B | −₩17.0B | −₩5.4B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| JW | 096760.KS | ₩4,105.00 | ₩284.03B |
| AptaBio Therapeutics | 293780.KQ | ₩7,940.00 | ₩223.06B |
| REYON Pharmaceutical | 102460.KS | ₩10,280.00 | ₩188.55B |
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| Chong Kun Dang | 001630.KS | ₩37,250.00 | ₩177.33B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
| Ilyang Pharmaceutical | 007570.KS | ₩7,950.00 | ₩142.50B |
| SAMSUNG PHARM. | 001360.KS | ₩1,376.00 | ₩129.51B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Jeil Pharmaceutical from India
What Jeil Pharmaceutical does
Primarily active within South Korea, Jeil Pharmaceutical Co.,Ltd dedicates itself to the development and supply of a broad spectrum of pharmaceutical goods. Its product offerings address numerous therapeutic categories, including antibiotics, gastrointestinal health, cardiovascular conditions, neuropsychiatric disorders, cancer (oncology), endocrine imbalances, urological issues, viral infections, and antihistamine remedies. Jeil Pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Jeil Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.